12:53 PM
 | 
Nov 02, 2018
 |  BC Week In Review  |  Company News  |  Deals

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis.

The partners will conduct preclinical and Phase I trials of tropifexor with one or more of Pfizer's compounds. The financial terms of the non-exclusive deal were not disclosed.

The Pfizer compounds are all in...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >